Active ingredient
Tirzepatide: FDA Status, Uses, Safety and Cost
Two receptor targets (GIP + GLP-1)
What Tirzepatide is
Tirzepatide is a dual-action medication that activates both GIP and GLP-1 hormone receptors — the first drug in this class. It is the active ingredient in two FDA-approved brands: Zepbound (approved for chronic weight management and obstructive sleep apnea in adults with obesity) and Mounjaro (approved for type 2 diabetes). There is no FDA-approved generic tirzepatide.
Key facts
| Generic (active ingredient) | Tirzepatide |
|---|---|
| Brand names | Zepbound, Mounjaro |
| Drug class | Dual GIP and GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company |
| FDA status | FDA ApprovedApproved for chronic weight management |
| Administration | Subcutaneous injection |
| Frequency | Once weekly |
| Approval date | First tirzepatide approval: May 2022 (Mounjaro). Weight-management approval: November 2023 (Zepbound). |
| Prescription required | Yes |
| Official label | Prescribing information (DailyMed) |
What Tirzepatide is approved for
- Chronic weight management (as Zepbound) in adults with obesity, or overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity
- Moderate-to-severe obstructive sleep apnea in adults with obesity (as Zepbound)
- Type 2 diabetes (as Mounjaro) — a different indication from weight management
How Tirzepatide works
Tirzepatide activates receptors for two incretin hormones, GIP and GLP-1. Per official labeling, it reduces body weight by decreasing calorie intake, with effects on appetite regulation and slowed gastric emptying.
- 1
Medication binds
A GLP-1 receptor agonist activates the receptor for the natural GLP-1 hormone.
- 2
Signals are sent
Appetite-regulating areas of the brain are affected, increasing fullness.
- 3
Stomach slows
Gastric emptying slows, so food stays in the stomach longer.
- 4
Intake falls
Per FDA labeling, weight reduction happens mainly through eating fewer calories.
Administration
Tirzepatide is given by subcutaneous injection, once weekly.
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
Boxed Warning — the FDA’s most serious warning
Risk of thyroid C-cell tumors: caused thyroid C-cell tumors in rodents at clinically relevant exposures; it is unknown whether this occurs in humans. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Summarized from the product’s FDA prescribing information. Read the full label, linked in Sources below.
Contraindications (who should not take it)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or product components
Summarized from the FDA prescribing information. This is not the complete list — see the full label.
Common adverse reactions from official labeling
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Dyspepsia (indigestion)
- Injection site reactions
- Fatigue
The most common adverse reactions listed in the product’s FDA prescribing information. Frequency and full adverse-reaction data are in the label.
Brand and generic relationships
Tirzepatide is the active ingredient in the following FDA-approved brand products.
Cost and access
- Tirzepatide products are available only by prescription from a licensed clinician.
- There is no FDA-approved generic tirzepatide; "compounded tirzepatide" products are not FDA approved.
- Eli Lilly offers a Zepbound savings card for eligible commercially insured patients and sells certain Zepbound single-dose vials through its LillyDirect self-pay channel; terms and pricing change — verify on the manufacturer site.
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Plans commonly cover Mounjaro for type 2 diabetes while excluding Zepbound for weight management — coverage is indication-specific.
- Employer plans vary widely on weight-management drug coverage; prior authorization is common when covered.
More detail: how insurance coverage works for weight-loss medication.
Comparisons
Frequently asked questions
- Is tirzepatide FDA approved for weight loss?
- Yes — as the brand Zepbound, tirzepatide is FDA approved for chronic weight management in adults who meet label criteria, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro contains the same ingredient but is approved for type 2 diabetes.
- How is tirzepatide different from semaglutide?
- Semaglutide activates one hormone receptor (GLP-1); tirzepatide activates two (GIP and GLP-1). They are made by different manufacturers and have separate FDA-approved products. See our semaglutide vs. tirzepatide comparison for a sourced side-by-side.
- Is there a generic tirzepatide?
- No. As of our last review there is no FDA-approved generic tirzepatide. Compounded versions sold online are not FDA-approved products.
Related guides
Sources
- Tirzepatide prescribing information (DailyMed, NIH) — DailyMed/NIH. Link last verified August 12, 2026.
- Drugs@FDA database — FDA. Link last verified August 12, 2026.
- FDA: concerns with unapproved GLP-1 drugs — FDA. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.